Browsing Tag
Gan & Lee Pharmaceuticals
6 posts
Lupin (NSE: LUPIN) signs licensing deal with Gan & Lee for Bofanglutide GLP-1 in India
Lupin signs exclusive India deal for Bofanglutide, a novel fortnightly GLP-1. Find out how it could reshape the obesity and diabetes market in 2026.
Gan & Lee Pharmaceuticals reveals competitive Phase 2 results for bofanglutide and GZR4 at ADA 2025 sessions
Gan & Lee Pharmaceuticals presented strong Phase 2 results for bofanglutide and GZR4 in type 2 diabetes, advancing its long-acting diabetes pipeline.
Neodyne Biosciences and Gan & Lee Pharmaceuticals reveal major clinical advances in diabetes care at ADA 2025
Neodyne Biosciences and Gan & Lee Pharmaceuticals presented major ADA 2025 clinical results showing new treatment paths for lipohypertrophy and type 2 diabetes.
Gan & Lee Pharmaceuticals begins US Phase 2 trial of bofanglutide for obesity and weight management
Gan & Lee Pharmaceuticals (Shanghai Stock Exchange: 603087) has initiated its Phase 2 clinical trial of bofanglutide (GZR18)…
Gan & Lee gets EMA orphan drug status for GLR2007 in glioma
Gan & Lee Pharmaceuticals has been granted orphan drug designation for GLR2007 from the European Medicine Agency (EMA)…
Gan & Lee gets FDA orphan drug status for GLR2007 in malignant glioma
Gan & Lee Pharmaceuticals has been given orphan drug designation from the US Food and Drug Administration (FDA)…